Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lanifibranor · IVA-337

Small molecule · developed by Inventiva Pharma

Phase 3 Most advanced trial
IVA Developer
2 Registered trials

What is Lanifibranor?

Lanifibranor (also known as IVA337) is an oral drug studied in nonalcoholic steatohepatitis and type 2 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IVA-337
Drug type
Small molecule
Therapy area
Gastroenterology, Metabolic
Developer
Inventiva Pharma (IVA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
28Q8AG0PYL

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04849728 Phase 3 NASH - Nonalcoholic Steatohepatitis Active not recruiting IVA
NCT05232071 Phase 2 NASH - Nonalcoholic Steatohepatitis Completed IVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

NASH - Nonalcoholic SteatohepatitisDiabetes Mellitus, Type 2

More from Inventiva Pharma

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IVA page.

Follow IVA, the company behind Lanifibranor

See IVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IVA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.